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background: Aspirin is integral to the antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI). The correlation 
between high on-clopidogrel treatment platelet reactivity (HCTPR) and clinical outcome is well established. For high on-aspirin treatment platelet 
reactivity (HATPR) no such clear association has been reported yet. The aim of the ISAR-ASPI registry was to assess the prognostic value of HATPR in 
PCI-treated patients with regard to the clinical outcome. 
methods: We identified a total of 7090 consecutive PCI-treated patients with pretreatment of aspirin. Directly before PCI, platelet function was 
assessed on a Multiplate analyzer. The primary end point was defined as death or stent thrombosis (ST) at one year. 
results: The upper quintile of patients (n=1414) according to Multiplate measurements was defined as the HATPR cohort. Compared to non-
HATPR patients (n = 5676), HATPR patients showed a significantly higher risk for death or ST at one year (6.2% vs. 3.7%; odds ratio [OR]: 1.78; 95% 
confidence interval [CI]: 1.39-2.27; p<0.0001, see Fig.1). The risk for cardiovascular death was 4.2% in HATPR versus 1.9% in non-HATPR patients 
(OR: 2.27; 95% CI: 1.67-3.09; p<0.0001). 
conclusion: HATPR, measured at the time point of the PCI, is associated with a higher risk for death or ST during the first year post PCI. Present 
data is observational and its implications warrant further investigations in dedicated studies.
 
